SOPHiA GENETICS (SOPH) President Muken Ross Receives Award

What Happened
Muken Ross, President of SOPHiA GENETICS SA (SOPH), received equity awards on April 2, 2026: 431,211 restricted stock units (RSUs) and 628,743 derivative awards (share options), for a total of 1,059,954 share-equivalents. Both grants were reported at $0.00 (no cash paid at grant); these are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-04-02; Form 4 filed 2026-04-03 (next day).
• Grant amounts/prices: 431,211 RSUs @ $0.00; 628,743 derivative awards @ $0.00. Total = 1,059,954.
• Shares owned after transaction: Not disclosed in the filing.
• Vesting notes (from filing):
  • RSUs: 25% vest on April 2, 2027; remaining 75% vest in equal quarterly installments through April 2, 2030. (F1)
  • Options: 25% vests on April 2, 2027; remaining vest in equal monthly installments through April 2, 2030. (F2)
• Timeliness: Filing appears timely (filed the day after the grant); no late filing indicated.

Context
These are compensation grants (RSUs and options) that convert to actual shares only as they vest; they do not represent an immediate purchase or sale. Derivative awards (options) give the holder a future right tied to vesting; exercise (and any subsequent sale) would be reported separately. Such grants are common executive compensation and, by themselves, are not a direct market signal.